Clinical trial
A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single and Multiple Doses of KR23248 Capsules in Healthy Adult Subjects
NCT07585383 is registered in ClinicalTrials.gov with Jiangxi Kvvit Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Single and Multiple Doses of KR23248 Capsules in Healthy Adult Subjects
- Lead sponsor
- Jiangxi Kvvit Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- May 19, 2026
- Completion date
- November 30, 2026
- Enrollment
- 66 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.